A panelist discusses how the new doravirine and islatravir combination offers an alternative to integrase inhibitor-based therapies, particularly useful for patients with integrase inhibitor resistance or adverse reactions, although clinicians may struggle with determining the ideal patient population.
Switch Study From Any Prior Antiretroviral Therapy
Key Themes:
Notable Insights From Dr Sharon Walmsley:
For Better Cancer Outcomes, It’s All About Access
August 21st 2025New drugs aren't the only advances in oncology. Innovation includes collaboration between to remove barriers to remove barriers to care, according to experts who gathered for a session of the Institute for Value-Based Medicine in Arlington, Virginia.
Read More